This study is for people with a type of blood cancer called Peripheral T-Cell Lymphoma (PTCL). The study is testing if adding either duvelisib or CC-486 to the usual chemotherapy works better than just the usual drugs alone. Chemotherapy is a treatment using strong medicines to stop cancer cells from growing. The usual chemotherapy in this study includes drugs like cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone.

Key Points:

• You will be in one of three groups, getting different treatments for up to 6 cycles (about 18 weeks total).
• You'll have regular check-ups during and after treatment to track progress and side effects.
• This study involves some risks, such as side effects from the medicines, but it may help find better treatments for PTCL in the future.

To join, you must be 18 or older, have not had PTCL treatment before, and meet other health requirements. Women who can have children need a negative pregnancy test before starting. If you have certain infections or other cancers, you might not be able to participate. The study will last for several years to monitor long-term effects.